Jove
Visualize
Contact Us

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating Associations Between Cumulative Use of Chronic Liver Injury-Inducing Antiretroviral Therapy and Hepatocellular Carcinoma, By Chronic Liver Disease Status.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

Helicobacter pylori infection and metabolic dysfunction-associated steatotic liver disease: a prospective study and meta-analysis.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular Carcinoma.

Liver cancer·2026
Same author

Health inequalities in patients with cirrhosis: Investigating the impact of material deprivation on patients' outcomes.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same author

Practice changing RCT design and rationale: Abbreviated MRI plus AFP <i>vs.</i> ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study).

JHEP reports : innovation in hepatology·2026
Same author

Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening.

Gastroenterology·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 31, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Systemic therapy in hepatocellular carcinoma.

Stephen H Wrzesinski1, Tamar H Taddei, Mario Strazzabosco

  • 1Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT 06520-8019, USA.

Clinics in Liver Disease
|June 22, 2011
PubMed
Summary
This summary is machine-generated.

Hepatocellular carcinoma (HCC) treatment requires personalized systemic therapies. Understanding HCC

More Related Videos

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Related Experiment Videos

Last Updated: May 31, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Area of Science:

  • Hepatocellular Carcinoma (HCC) Research
  • Oncology
  • Molecular Pathology

Background:

  • Hepatocellular carcinoma (HCC) incidence is rising, with most patients diagnosed at advanced stages.
  • Traditional cytotoxic chemotherapies showed limited efficacy, leading to the development of locoregional therapies.
  • Locoregional therapies have improved overall survival for HCC patients.

Purpose of the Study:

  • To explore the need for personalized systemic therapies in hepatocellular carcinoma (HCC) treatment.
  • To highlight the importance of understanding molecular and genetic pathways in HCC.
  • To emphasize the role of cirrhosis pathobiology in guiding treatment decisions.

Main Methods:

  • Review of current systemic therapies under investigation for HCC.
  • Analysis of the molecular and genetic landscape of HCC.
  • Evaluation of the pathobiology of cirrhosis in relation to HCC.

Main Results:

  • Current systemic therapies are under investigation for advanced HCC.
  • Personalized therapy necessitates stratification by disease stage and population.
  • Understanding molecular pathways and cirrhosis pathobiology is crucial for effective treatment.

Conclusions:

  • Truly personalized HCC therapy requires a deep understanding of molecular and genetic pathways.
  • Integrating knowledge of disease stage, population, and cirrhosis pathobiology is essential.
  • Tailoring therapies to individual patients will significantly prolong survival in HCC.